ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2020

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China.

Peng Men et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.